GlassScriptPhysician profile
Zilla F Henricksen
NPI 1578934790
$9,444.58
in general payments reported to CMS, 2019-2025
30 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $844 · 2022: $1,682 · 2023: $2,282 · 2024: $2,355 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,907.07 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,482.62 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,071.44 | 2021-2025 | |
| Alkermes, INC. | $868.52 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $804.44 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $783.26 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $759.20 | 2021-2025 | Ingrezza |
| Corium, LLC | $644.21 | 2023-2025 | Azstarys |
| Neos Therapeutics, LP | $504.59 | 2021-2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $422.42 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $343.31 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $233.88 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $185.01 | 2021-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $184.85 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $150.19 | 2021-2025 | Trintellix |
| Livanova USA, INC. | $131.12 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $119.42 | 2022-2024 | Qelbree, Qelbree |
| Bausch Health US, LLC | $101.43 | 2021-2025 | Aplenzin |
| Indivior INC. | $94.31 | 2024-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $88.22 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $72.07 | 2021-2022 | |
| Eisai INC. | $70.96 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $67.47 | 2025 | Austedo Xr |
| Almatica Pharma LLC | $63.35 | 2021-2024 | Loreev Xr |
| Noven Therapeutics, LLC | $43.24 | 2024-2025 | Xelstrym, Secuado |
| Aytu Biopharma, INC. | $39.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.73 | 2021 | |
| Merck Sharp & Dohme LLC | $29.61 | 2022 | |
| Collegium Pharmaceutical, INC. | $23.72 | 2025 | Jornay Pm |
| Abbott Laboratories | $14.65 | 2024 | Alinity |
| Novo Nordisk INC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zilla Henricksen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.